, (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced  that a  global biopharmaceutical services provider has signed a MSA, licensing NewCardio's QTinno™ software solution to enhance its delivery of fully automated cardiac safety analyses for early phase QT studies. The CRO is expected to deploy QTinno in several clinical unit locations worldwide.

In addition, the CRO has signed a services work order related to the first study using QTinno, which is scheduled to be initiated this June.


NewCardio to Perform First Revenue-Generating QT Study Using QTinno